EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Evolution of nanomedicine formulations for targeted delivery and controlled release

Sanyogitta Puri, Mariarosa Mazza, Gourgopal Roy, Richard M England, Liping Zhou, Saghar Nourian, J Anand Subramony

Advanced Drug Delivery Reviews · 2023-09 · 200 · 114962

DOI: 10.1016/j.addr.2023.114962 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-09. Verfasst von Sanyogitta Puri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Nanomedicine, Nanoparticles. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanotechnology research over the past several decades has been aimed primarily at improving the physicochemical properties of small molecules to produce druggable candidates as well as for tumor targeting of cytotoxic molecules. The recent focus on genomic medicine and the success of lipid nanoparticles for mRNA vaccines have provided additional impetus for the development of nanoparticle drug carriers for nucleic acid delivery, including siRNA, mRNA, DNA, and oligonucleotides, to create therapeutics that can modulate protein deregulation. Bioassays and characterizations, including trafficking assays, stability, and endosomal escape, are key to understanding the properties of these novel nanomedicine formats. We review historical nanomedicine platforms, characterization methodologies, challenges to their clinical translation, and key quality attributes for commercial translation with a view to their developability into a genomic medicine. New nanoparticle systems for immune targeting, as well as in vivo gene editing and in situ CAR therapy, are also highlighted as emerging areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanomedicineNanoparticlesHumansDrug Delivery SystemsDelayed-Action PreparationsNanotechnologyRNA, Messenger

Substanzen

Delayed-Action PreparationsRNA, Messenger

Autor:innen und Institutionen

  • Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: mariarosa.mazza@astrazeneca.com.
  • Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Biologics Engineering, Oncology R&D, United States.
  • Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Macclesfield, UK.
  • Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
  • Emerging Innovations Unit, Discovery Sciences, Biopharmaceutical R&D , AstraZeneca, Gaithersburg, MD, USA.

Förderung

  • AstraZeneca

Zitieren

APA

Puri, S., Mazza, M., Roy, G., England, R. M., Zhou, L., Nourian, S., & Anand Subramony, J. (2023). Evolution of nanomedicine formulations for targeted delivery and controlled release. Advanced Drug Delivery Reviews, 200, 114962. https://doi.org/10.1016/j.addr.2023.114962

Vancouver

Puri S, Mazza M, Roy G, England RM, Zhou L, Nourian S, et al. Evolution of nanomedicine formulations for targeted delivery and controlled release. Advanced Drug Delivery Reviews. 2023;200:114962. doi:10.1016/j.addr.2023.114962

BibTeX
@article{Puri2023,
  author = {Puri, Sanyogitta and Mazza, Mariarosa and Roy, Gourgopal and England, Richard M and Zhou, Liping and Nourian, Saghar and Anand Subramony, J},
  title = {Evolution of nanomedicine formulations for targeted delivery and controlled release},
  journal = {Advanced Drug Delivery Reviews},
  year = {2023},
  volume = {200},
  pages = {114962},
  doi = {10.1016/j.addr.2023.114962}
}
Kostenlos starten →